Today Novartis has published updated 2022 quarterly and full year segment financials reflecting transfers of Sandoz biotechnology manufacturing services to other companies’activities and the Coartem®brand from Sandoz to the Innovative Medicines Division，which were effective as of January12023.The2022updated segment financial reporting is provided in accordance with requirements of IFRS，and to aid comparability of 2023quarterly and full year results for the segments and Corporate。
Disclaimer:The information in the presentations on these pages was factually accurate on the date of publication.These presentations remain on the Novartis website for historical purposes only.Novartis assumes no responsibility to update the information to reflect subsequent developments.ders ould shold report in the informationges as current or accurate after their publication dates。
